Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1232.00
-13.50 (-1.08%)
< Home < Back

Dr Reddy's Laboratories launches Fenofibrate Tablets USP in US Market

Date: 27-04-2020

Dr Reddy's Laboratories has launched Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor (fenofibrate) Tablets, approved by the US Food and Drug Administration (USFDA). The Tricor brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.

The company’s Fenofibrate Tablets USP, are available in 54 mg dose in bottle count size of 90 and 160 mg dose in bottle count sizes of 90 and 500. Tricor is a trademark of AbbVie Inc.

Dr Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.